VanEck Biotech ETF (NASDAQ:BBH) Sees Significant Drop in Short Interest

VanEck Biotech ETF (NASDAQ:BBH) was the recipient of a significant decrease in short interest in April. As of April 15th, there was short interest totalling 2,500 shares, a decrease of 67.9% from the March 31st total of 7,800 shares. Based on an average trading volume of 7,200 shares, the days-to-cover ratio is presently 0.3 days.

VanEck Biotech ETF Trading Up 0.8 %

VanEck Biotech ETF stock traded up $1.20 during midday trading on Friday, reaching $155.97. 5,913 shares of the company were exchanged, compared to its average volume of 9,080. The firm’s 50-day simple moving average is $162.38 and its 200-day simple moving average is $159.79. VanEck Biotech ETF has a 1 year low of $142.51 and a 1 year high of $171.04.

Institutional Trading of VanEck Biotech ETF

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BBH. Commonwealth Equity Services LLC increased its position in VanEck Biotech ETF by 1.8% during the 3rd quarter. Commonwealth Equity Services LLC now owns 28,705 shares of the company’s stock worth $4,470,000 after purchasing an additional 495 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its position in VanEck Biotech ETF by 3.8% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 14,220 shares of the company’s stock worth $2,214,000 after purchasing an additional 521 shares in the last quarter. Altfest L J & Co. Inc. increased its position in VanEck Biotech ETF by 3.7% during the 3rd quarter. Altfest L J & Co. Inc. now owns 7,657 shares of the company’s stock worth $1,192,000 after purchasing an additional 274 shares in the last quarter. Assetmark Inc. acquired a new stake in VanEck Biotech ETF in the 3rd quarter worth about $135,000. Finally, Wealthfront Advisers LLC boosted its stake in VanEck Biotech ETF by 32.8% in the 3rd quarter. Wealthfront Advisers LLC now owns 5,229 shares of the company’s stock worth $814,000 after buying an additional 1,292 shares during the last quarter. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.